|
EPO906 in Carcinoid and other Neuroendocrine Tumors Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on EPO906 in Carcinoid and other Neuroendocrine Tumors conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. EPO906 in Carcinoid and other Neuroendocrine Tumors Clinical research trials and EPO906 in Carcinoid and other Neuroendocrine Tumors medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including EPO906 in Carcinoid and other Neuroendocrine Tumors. EPO906 in Carcinoid and other Neuroendocrine Tumors Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a EPO906 in Carcinoid and other Neuroendocrine Tumors clinical trial. Participants oftentimes recieve the finest healthcare available for their EPO906 in Carcinoid and other Neuroendocrine Tumors condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > EPO906 in Carcinoid and other Neuroendocrine Tumors  EPO906 in Carcinoid and other Neuroendocrine Tumors
EPO906 in Carcinoid and other Neuroendocrine Tumors
For Condition: Neuroendocrine Tumors,Carcinoid
Status: Suspended
Sponsor(s): Novartis Pharmaceuticals ,
Synopsis: This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause metastatic carcinoid and other neuroendocrine tumors.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/85 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Patients with biopsy-proven metastatic carcinoid tumors or other neuroendocrine tumors (Islet cell, Gastrinomas and VIPomas) with at least one measurable lesion (other than bone) that has either not been previously irradiated or if previously irradiated has demonstrated progression since the radiation therapy - The patient has no major impairment of renal or hepatic function, as defined by the following laboratory parameters: total bilirubin <1.5 X ULN; AST, ALT<2.5X ULN (<5 X ULN if liver metastases are present) - Patients on Sandostatin Lar (long acting somatostatin analogue) must be on a stable dose for 30 days prior to study entry and short acting somatostatin analogues must be judged to be on a clinically stable dose by the investigator prior to study entry - Must have a life expectancy of greater than three (3) months - Karnofsky Performance Status > 60 - Female patients must have a negative serum pregnancy test at screening. (Not applicable to patients with bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal.) Exclusion Criteria: - Patients with symptomatic CNS metastases or leptomeningeal involvement - Patients with known brain metastases, unless these metastases have been treated and/or have been stable for at least six months prior to study start. Subjects with a history of brain metastases must have a head CT with contrast to document either response or progression. - Patients with bone metastases as the only site(s) of measurable disease - Patients with hepatic artery chemoembolization within the last 6 months (one month if there are other sites of measurable disease) - Patients who have been previously treated with radioactive directed therapies - Patients who have been previously treated with epothilone - Patients with any peripheral neuropathy or unresolved diarrhea greater than Grade 1 - Patients with severe cardiac insufficiency patients taking Coumadin or other warfarin-containing agents with the exception of low dose warfarin (1 mg or less) for the maintenance of in-dwelling lines or ports - Patients taking any experimental therapies history of another malignancy within 5 years prior to study entry except curatively treated non-melanoma skin cancer, prostate cancer, or cervical cancer in situ - Patients with active or suspected acute or chronic uncontrolled infection including abcesses or fistulae - Patients with a medical or psychiatric illness that would preclude study or informed consent and/or history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits - HIV+ patients - Pregnant or lactating females.
Total Enrollment: 48
Location and Contact Information:
Oregon Health and Sciences University
Portland, Oregon,
United States
Louisiana State University Medical Center
New Orleans, Louisiana,
United States
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida,
United States
University of Iowa Holden Cancer Center
Iowa City, Iowa, 52242
United States
Weill Medical College at Cornell University, Dept. Hem/Onc
New York City, New York,
United States
Northwestern/Hematology Oncology Clinic
Chicago, Illinois, 60611
United States
Additional Information:
Study ID Numbers: CEPO906A2212;
Study Start Date: July 2002
Record last reviewed: December 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00050349
Other Carcinoid Studies:
1. High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors
2. EPO906 in Carcinoid and other Neuroendocrine Tumors
Related Studies:
Other Carcinoid Clinical Trials
Other Florida Clinical Trials
Other Tampa Clinical Trials
EPO906 in Carcinoid and other Neuroendocrine Tumors
|
|
|
|
|
|
|
|
